ESPERA study: Applicability of the new ILAE criteria for antiepileptic drug resistance of focal epilepsies in current clinical practice

Abstract A European observational cross-sectional study, ESPERA, was conducted in France and Spain in 2010. A random sample of neurologists, including specialists in epilepsy, prospectively enrolled adult patients treated for focal epilepsy with at least two antiepileptic drugs (AEDs) in combination...

Full description

Saved in:
Bibliographic Details
Published in:Epilepsy & behavior 2012-10, Vol.25 (2), p.166-169
Main Authors: de Toffol, Bertrand, de Zélicourt, Marie, Vespignani, Hervé, Fagnani, Francis, Laurendeau, Caroline, Lévy-Bachelot, Laurie, Murat, Christina, Gasalla, Teresa, Arzimanoglou, Alexis, Villanueva, Vicente
Format: Article
Language:English
Subjects:
Adult
Anticonvulsants - therapeutic use
Classification
Cross-Sectional Studies
Drug resistance
Epilepsies, Partial - drug therapy
Focal epilepsies
France
Humans
Neurology
Research Design
Spain
Treatment Failure
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract A European observational cross-sectional study, ESPERA, was conducted in France and Spain in 2010. A random sample of neurologists, including specialists in epilepsy, prospectively enrolled adult patients treated for focal epilepsy with at least two antiepileptic drugs (AEDs) in combination. Investigators were asked to classify AED responsiveness of each enrolled patient according to the new 2009 ILAE criteria. These classifications were then reviewed by three experts. Potential factors of misclassification were then analyzed in order to evaluate the applicability of the new ILAE criteria for antiepileptic drug resistance in current clinical practice. Because of their complexity, use of the new ILAE criteria needs to be supported by relevant information and training to be adequately applied by neurologists in everyday practice.
ISSN:1525-5050
1525-5069
DOI:10.1016/j.yebeh.2012.08.005